Pre-made Elipovimab benchmark antibody ( Whole mAb, anti-HIV-1 gp120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-171
Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||4fq1:HL/4jy4:BA/4fqc:HL|
|Conditions Active||HIV infections|